HbA(1c) Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial

OBJECTIVE: To evaluate participant characteristics and long-term changes in glycated hemoglobin (HbA(1c)) levels in patients treated with dulaglutide 1.5 mg in a post hoc analysis of the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial. RESEARCH DESIGN AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwan, Anita Y.M., Gerstein, Hertzel C., Basile, Jan, Xavier, Denis, Maldonado, Juan M., Raha, Sohini, Konig, Manige
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Clinical Care/Education/Nutrition/Psychosocial Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918189/
https://www.ncbi.nlm.nih.gov/pubmed/35043140
http://dx.doi.org/10.2337/dc21-1160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918189/
https://www.ncbi.nlm.nih.gov/pubmed/35043140
http://dx.doi.org/10.2337/dc21-1160

Ejemplares similares